Fatness Epidemic Kills More People Each Day Than Covid Ever Did

[rebelmouse-proxy-image https://thefederalist.com/wp-content/uploads/2024/04/Screenshot-2024-04-09-at-5.20.39 PM-1200x675.png crop_info="%7B%22image%22%3A%20%22https%3A//thefederalist.com/wp-content/uploads/2024/04/Screenshot-2024-04-09-at-5.20.39%5Cu202fPM-1200x675.png%22%7D" expand=1]Why are there no daily warnings recounting the number of people who die from heart disease, diabetes, and other issues directly caused by crappy metabolic health?

Gender Studies Professor Blasts Fight Against Obesity As ‘Fatphobic’

A Canadian gender studies professor claims new drugs deployed in the fight against obesity are fatphobic.

Skittles Panders To Black Americans While Selling Them Prepackaged Diabetes

Corporations selling harmful food products have chimed in to demonstrate their faux morality and obsession with the plight of black America.

Reports: Apple Watch developers hit major milestone in bringing no-prick blood glucose monitoring to market



A secretive team at Apple Inc. is developing wearable, no-prick, continuous blood glucose monitoring for its Apple Watch, Bloomberg reported.

"Really the holy grail for a smartwatch is to be able to tell you all of your health metrics, and one of the most important health metrics ... is blood sugar or blood glucose monitoring," said Bloomberg's Mark Gurman.

"Apple wants to create a system using chips, sensors, software algorithms built in to the Apple Watch," said Gurman, who explained that current, more invasive methods involve a finger stick or a blood draw. The technology Apple is developing requires no blood sample.

The secret project, called "E5," hit major milestones recently, and Apple believes it may eventually bring noninvasive, continuous blood glucose monitoring to market, Bloomberg reported in a separate piece last week. No pricking would be required.

Gurman said a measurement process called "optical absorption spectroscopy" and a chip technology called "silicon photonics" make the seemingly impossible feat a reality. The watch uses lasers in such a way that the concentration of glucose in a person's interstitial fluid can be estimated with a special algorithm.

An unidentified person familiar with the confidential initiative told Bloomberg the project is at the proof-of-concept stage.

One major hurdle still to be overcome involves the physical size of the device. An early version "sat atop a table," Bloomberg reported. Today, engineers are focused on getting it down to the size of an iPhone that would be strapped to a person's bicep. Ultimately, the tech could be integrated into the Apple Watch.

Apple's Exploratory Design Group, XDG, is in charge of the moonshot-like project. XDG comprises primarily "engineers and academic types," Bloomberg says. It was originally run by Bill Athas, who passed away suddenly in 2022.

Senior Vice President Johny Srouji now sits at XDG's helm. Top engineers and scientists on the glucose project include Jeff Koller, Dave Simon, and Bryan Raines, according to Bloomberg.

One major goal is to give both diabetic and non-diabetic people actionable information on their health. For non-diabetic people, the technology could allow them to take action, like changing eating habits or exercising, if their glucose levels suggested trouble.

For people with diabetes — more than 34.2 million in the United States, according to the Diabetes Research Institute Foundation — the technology could mean a welcome relief from pricking their fingers multiple times a day or wearing disposable monitors that also involve a prick.

Like Blaze News? Bypass the censors, sign up for our newsletters, and get stories like this direct to your inbox. Sign up here!

The Pro-Abortion ‘Life Of The Mother’ Argument Is A False Flag Operation

Women face many possible illnesses during pregnancy, but intentional feticide is never necessary even in the worst-case scenarios.

Dismal: American Workers Throttled By Inflation, High On Drugs, And Low On Life

With deteriorating personal finances and baseline health, it's no surprise that a declining number of Americans claim to be 'thriving.'

Biden administration freezes Trump's directive to lower insulin prices



In his first days in office, President Joe Biden went on a blitz of reversing or halting policies implemented by former President Donald Trump. Included in the flurry of executive orders and directives, the Biden administration paused a measure that was designed to decrease the price of insulin.

Trump signed off on the "Access to Affordable Life-Saving Medications" rule on Dec. 23, 2020. The rule was to enable "improved access to these life-saving medications by low-income individuals who do not have access to affordable insulin and injectable epinephrine due to either lack of insurance or high cost sharing requirements."

The rule was set to go into effect on Jan. 22, 2021, but it was shot down by the Biden administration. On Wednesday, the Department of Health and Human Services announced that the directive would be frozen for 60 days.

"The temporary delay in the effective date of this final rule is necessary to give Department officials the opportunity for further review and consideration of new regulations, consistent with the memorandum of January 20, 2021, from the Assistant to the President and Chief of Staff, entitled 'Regulatory Freeze Pending Review,'" the HHS said.

White House chief of staff Ron Klain sent out a memo on Wednesday that directed agencies to freeze all of Trump's last-minute or "midnight regulations." The action to freeze Trump's last regulations will "give the incoming Administration an opportunity to review any regulations that the Trump Administration tried to finalize in its last days," according to the Biden administration.

The directive that orders certain health centers to pass discounts they get on insulin and epinephrine directly to their patients will be frozen until March 22.

As of 2020, "34.2 million Americans — just over 1 in 10 — have diabetes, and another 88 million American adults—approximately 1 in 3—have prediabetes," according to the Centers for Disease Control and Prevention.

"In 2016, the U.S. Centers for Medicare & Medicaid Services (CMS) estimated that Medicare spent $42 billion more for beneficiaries over age 65 with type 2 diabetes than for those who do not have the disease," the CDC stated.

The Kaiser Family Foundation, a nonprofit organization focusing on national health issues, reported that the "average total Medicare Part D spending per user on insulin products increased by 358% between 2007 and 2016, from $862 to $3,949."

As far as insulin sales in the United States, there are the "big three" pharmaceutical giants: Eli Lilly and Company, Sanofi, and Novo Nordisk.

A report from the offices of Sens. Chuck Grassley (R-Iowa) and Ron Wyden (D-Ore.), leaders of the Senate Finance Committee, investigated the soaring insulin prices, and found a "broken" system to blame.

"This investigation makes clear that consumers are the only ones losing out in America's broken drug pricing system, since every part of the pharmaceutical supply chain benefits from higher list prices," Wyden said in a statement.

Novo Nordisk and Sanofi reportedly engaged in a "cat-and-mouse strategy of pricing," where the pharmaceutical companies would match or increase prices any time the competitor raised its prices.